1. Home
  2. PCOR vs ABVX Comparison

PCOR vs ABVX Comparison

Compare PCOR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PCOR

Procore Technologies Inc.

HOLD

Current Price

$58.98

Market Cap

8.5B

Sector

Technology

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$117.58

Market Cap

9.7B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCOR
ABVX
Founded
2003
2013
Country
United States
France
Employees
N/A
67
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
9.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
PCOR
ABVX
Price
$58.98
$117.58
Analyst Decision
Buy
Buy
Analyst Count
19
13
Target Price
$77.42
$130.85
AVG Volume (30 Days)
2.2M
770.7K
Earning Date
04-30-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
6.94
N/A
EPS
N/A
N/A
Revenue
$1,322,509,000.00
N/A
Revenue This Year
$15.24
N/A
Revenue Next Year
$12.99
$0.22
P/E Ratio
N/A
N/A
Revenue Growth
14.83
N/A
52 Week Low
$46.08
$4.77
52 Week High
$82.32
$148.83

Technical Indicators

Market Signals
Indicator
PCOR
ABVX
Relative Strength Index (RSI) 55.55 48.39
Support Level $54.68 $106.37
Resistance Level $59.67 $131.27
Average True Range (ATR) 2.09 5.05
MACD 0.44 0.58
Stochastic Oscillator 71.99 53.55

Price Performance

Historical Comparison
PCOR
ABVX

About PCOR Procore Technologies Inc.

Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: